ong-lasting changes in cellular functions require reprogramming of protein synthesis as a result of cell signaling events that influence nuclear transcription and͞or the fate of the transcribed mRNAs, ultimately leading to changed mRNA availability to the ribosome. Posttranscriptional mechanisms are emerging as key controllers of gene expression (reviewed in refs. 1 and 2) and are postulated to be critical for the localized changes in protein levels involved in cell differentiation and in the maintenance of the differentiated phenotype, especially in polarized cells such as neurons (3). Modulation of mRNA decay appears to be an efficient posttranscriptional way of controlling expression, because small changes in mRNA half-life can radically alter the abundance of a given mRNA and the amount of the relevant protein (4). Indeed, the decay rates of many mRNAs are governed by defined sequence determinants and by RNA-binding proteins (RBPs) acting on these determinants. The best-characterized regulative cis motifs in mammalian mRNAs are the AREs (adenine-and uridine-rich elements), which are found in the 3Ј UTRs of mRNAs endowed with a rapid response to cell environmental stimuli, as in many cytokines and oncogenes (reviewed in ref. 5).
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ong-lasting changes in cellular functions require reprogramming of protein synthesis as a result of cell signaling events that influence nuclear transcription and͞or the fate of the transcribed mRNAs, ultimately leading to changed mRNA availability to the ribosome. Posttranscriptional mechanisms are emerging as key controllers of gene expression (reviewed in refs. 1 and 2) and are postulated to be critical for the localized changes in protein levels involved in cell differentiation and in the maintenance of the differentiated phenotype, especially in polarized cells such as neurons (3) . Modulation of mRNA decay appears to be an efficient posttranscriptional way of controlling expression, because small changes in mRNA half-life can radically alter the abundance of a given mRNA and the amount of the relevant protein (4) . Indeed, the decay rates of many mRNAs are governed by defined sequence determinants and by RNA-binding proteins (RBPs) acting on these determinants. The best-characterized regulative cis motifs in mammalian mRNAs are the AREs (adenine-and uridine-rich elements), which are found in the 3Ј UTRs of mRNAs endowed with a rapid response to cell environmental stimuli, as in many cytokines and oncogenes (reviewed in ref. 5 ).
In the human genome, a general ARE consensus is present in 5-8% of expressed genes (6) , and it represents a docking site for RBPs controlling mRNA stability, probably by modulation of exosome activity (7) . ARE-dependent mRNA decay has been shown to be a target of at least two signaling cascades. The first is the p38 mitogen-activated protein kinase (MAPK)-MAPKAPK2 pathway, which, when activated, stabilizes ARE-bearing interleukin mRNAs (8) (9) (10) , possibly through inactivation of the ARE-binding, mRNA-destabilizing RBP tristetraprolin (11, 12) . The second pathway, which has been less investigated, is triggered by phorbol esters (phorbol 12-myristate 13-acetate, PMA) and calcium ionophore administration to culture cells, leading again to stabilization of ARE-bearing mRNAs (13) (14) (15) (16) (17) (18) (19) . For its features, this pathway could involve the calcium-and diacylglycerol-regulated PKC isozymes, possibly resulting in the activation of a downstream function able to induce stabilization of ARE-bearing mRNAs. Fifteen years ago, Malter and coworkers (20, 21) identified a factor of Ϸ32 kDa, which they called AUBF for AU-rich binding factor, that was induced to bind ARE sequences after brief PMA treatment or calcium influx and was inactivated by dephosphorylation in peripheral blood mononuclear cells. AUBF was shown to be almost entirely located on polysomes when stimulated (22) .
ELAV (embryonic lethal abnormal vision) proteins, or Hu antigens, represent the best-studied ARE-binding RBPs and are known from a substantial body of evidence to stabilize target mRNAs in the cytoplasm (reviewed in refs. 23 and 24) . In vertebrates, HuB, HuC, and HuD are neuron-specific members of the ELAV family (nELAV proteins), whereas HuR is ubiquitously expressed; all four proteins are highly homologous in sequence, are Ϸ40 kDa in size, and contain three Ϸ90-aa-long RNA recognition motif-type RNA-binding domains (25) . ELAV proteins shuttle between the nucleus and the cytoplasm (26) (27) (28) (29) and, in the cytoplasm, can colocalize with polysomes and with the cytoskeletal apparatus (30) (31) (32) . In PC12 cells, genetic knock-down by antisense RNA expression of one of the nELAV proteins, HuD, blocks the neurite outgrowth phenotype induced by PMA in this neuronal differentiation model and prevents PKC-mediated stabilization of the ARE-bearing, HuD-bound growth-associated protein 43 (GAP-43) mRNA (33) .
In view of these and other features of ELAV RBPs, we hypothesized that these proteins represent a final target of the signaling cascade involving PKC and resulting in stabilization of AREbearing mRNAs. Employing a human neural cell model, SH-SY5Y neuroblastoma cells, and focusing on the well described activity of the nELAV proteins on the GAP-43 mRNA, we found that activation of PKCs by diacylglycerol analogues is indeed able to promote nELAV nuclear export, nELAV up-regulation, and nELAV cytoskeletal colocalization with the PKC␣ isozyme as early events, resulting in their increased phosphorylation. These changes were associated with the already described stabilization of GAP-43 mRNA. Unexpectedly, we also found that nELAV proteins activated in this way promote a compartmentalized increase of the GAP-43 protein. These results allowed us to define a previously unrecognized pathway, which we showed is also susceptible to in vivo pharmacological modulation, for the activity of nELAV proteins on their target mRNAs as positive modulators of gene expression in neural cells.
Materials and Methods
Cell Cultures. SH-SY5Y human neuroblastoma cells were grown in MEM (Eagle's minimal essential medium) supplemented with 10% FCS͞penicillin/streptomycin͞nonessential amino acids͞sodium pyruvate (1 mM) at 37°C in an atmosphere of 5% CO 2 and 95% humidity. The PKC␣-depleted, stably transfected SH-SY5Y-derived cell line (KD SH-SY5Y), was provided by Thomas B. Shea (McLean Hospital, Boston) and was obtained by transfection of a PKC␣ sequence in the antisense orientation (34) . The KD SH-SY5Y cell line was maintained in the same medium supplemented with the selecting agent G418 (400 g͞ml, GIBCO͞Life Technologies).
Treatments. In vitro. SH-SY5Y human neuroblastoma cells were exposed to the solvent (DMSO) or to 100 nM PMA (Sigma) for 15 min, as indicated in Results. The Ca 2ϩ -dependent PKC␣ inhibitor Gö6976 (Calbiochem) was used at 2 M concentration. 5,6-Dichlorobenzamidazole riboside (DRB) (Sigma) was used at a concentration of 50 M. Treatments were performed in Krebs-Ringer saline solution (pH 7.4) containing 20 mM Hepes, 125 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 1 mM MgSO 4 , 1 mM CaCl 2 , and 5.5 mM glucose. When the cells were prepared for SDS͞PAGE, the treatments were stopped with buffer A, which contained 20 mM Tris (pH 7.4), 2 mM EDTA, 0.5 mM EGTA, 50 mM mercaptoethanol, 0.32 mM sucrose, and a protease inhibitor mixture (Roche Diagnostics) at the dilution suggested by the manufacturer. In vivo. Eight-week-old male Wistar rats (250 g) received intracerebroventricular injections of DMSO (vehicle) or 2 M bryostatin-1 dissolved in DMSO. Animals were killed 24 h after treatments.
Preparation of the Cellular Fractions and Western Blotting. Subcellular fractioning (cytosol, membrane, and cytoskeleton) and Western blots were performed as described in ref. 35 Immunocytochemistry. Cells plated on coverslips were treated with 100 nM PMA or bryostatin-1 in Krebs-Ringer saline solution for 15 min, whereas control cells were incubated with DMSO (solvent). For detailed procedures see Supporting Materials and Methods. Briefly, a polyclonal antibody diluted 1:50 was used to recognize PKC␣ or ␣-tubulin; the mouse biotin-conjugated 16A11 diluted 1:50 was used as anti-nELAV (Molecular Probes). FITCconjugated rabbit anti-IgG antibody (Calbiochem) was diluted at 1:4,500 to detect PKC␣ and at 1:200 for ␣-tubulin; Texas redconjugated streptavidin (Calbiochem) was diluted at 1:100. Cells were counterstained for DNA with a 0.1 g͞ml Hoechst 33342 solution.
Real-Time Quantitative RT-PCR. Total RNA was extracted from SH-SY5Y and KD SH-SY5Y cells and from their cytosolic, membrane, and cytoskeletal subfractions with TRIzol reagent (Invitrogen), treated with DNase, and subjected to reverse transcription following standard procedures. PCR amplifications were carried out by using a Lightcycler instrument (Roche Diagnostics) as described in ref. 37 with primers designed on the 3Ј UTRs of the human GAP-43 and ribosomal protein L6 (RPL6) mRNA sequences by using PRIMER3 software (www-genome.wi.mit.edu͞cgi-bin͞primer͞primer3www.cgi). Primer sequences were as follows: GAP-43, 5Ј-GAGCCTGTCTCTCCCTACCC-3Ј (upstream) and 5Ј-TTGGGATCTTTCCTGCTTTTT-3Ј (downstream); RPL6, 5Ј-CACAAATTTTACCAAAAATCAAA-3Ј (upstream) and 5Ј-TTTAGAACACCAATTTGTGAGGA-3Ј (downstream). The RPL6 mRNA was chosen as the reference mRNA on which GAP-43 was normalized because it remained substantially stable in the 8-h time frame of the experiments with DRB (data not shown).
Immunohistochemistry. Rat brains were immediately removed and frozen to Ϫ80°C. Twenty-micrometer-thick cryostat sections were processed as described in ref. 37 . Nonspecific sites were blocked, and the slices were exposed to the mouse biotin-conjugated 16A11 anti-Hu (Molecular Probes) primary antibody diluted at 1:20 at 4°C overnight, followed by incubation with Streptavidin Alexa Fluor 488 (Molecular Probes) diluted at 1:400.
Data Analysis. Analysis of the data were performed with ANOVA followed by Student's t test as indicated by using the ORIGIN 6.1 statistical package (OriginLab, Northampton, MA) . Differences were considered statistically significant when P Յ 0.05.
Results

Diacylglycerol-Mimicking Compounds Promote Nuclear Export, Cytoskeletal Up-Regulation, and Cytoskeletal Binding of nELAV Proteins.
Fig . 1A shows that 15 min of treatment with PMA and bryostatin-1, two compounds that mimic diacylglycerol in binding and activating the diacylglycerol-responsive PKC isozymes, induced in SH-SY5Y human neuroblastoma cells a dramatic decrease of nuclear immunostaining by the mAb 16A11, targeted to the nELAV (HuB, HuC, and HuD) proteins. In addition, Western blotting data indicate that PMA and bryostatin-1 at the concentration used (100 nM for both) promote substantial translocation of the PKC␣ isozyme from the cytosol to either the membrane (ϩ50%, P Ͻ 0.0001 for PMA and ϩ42%, P Ͻ 0.005 for bryostatin-1) or the cytoskeletal (ϩ69%, P Ͻ 0.0001 for PMA and ϩ46%, P Ͻ 0.05 for bryostatin-1) compartments, demonstrating their efficacy as activators of conventional PKC isozymes in this cell model. PKC stimulation by both compounds is also associated with an increase in the total cell levels of nELAV proteins detected by Western blotting (ϩ56%, P Ͻ 0.01 for PMA and ϩ60%, P Ͻ 0.05 for bryostatin-1; Fig. 1B Top) . The same Western blotting repeated on SH-SY5Y cell fractions shows that the increased nELAV proteins are confined to the cytoskeletal compartment (ϩ59%, P Ͻ 0.001 for PMA and ϩ163%, P Ͻ 0.01 for bryostatin-1 in the cytoskeleton; Fig. 1B Bottom) . The increase of nELAV proteins in the cytoskeletal fraction induced by PKC stimulation is accompanied by the establishment of their physical association with the cytoskeletal protein ␣-tubulin, as demonstrated by both immunoprecipitation and immunocytochemistry assays. PMA treatment induced the appearance of the nELAV signal in the cytoskeleton immunoprecipitated with an ␣-tubulin antibody (ϩ47%, P Ͻ 0.05) but not with an isotype-matched irrelevant antibody (Fig. 1C) , and the same result (not shown) was obtained by immunoprecipitating with the 16A11 mAb and detecting with the ␣-tubulin antibody (ϩ40%, P Ͻ 0.05). This PKC-dependent interaction was confirmed by confocal imaging of SH-5YSY cells that were coimmunostained for ␣-tubulin and nELAV proteins, with the appearance of a superimposed signal only in the PMAtreated samples (Fig. 1D) .
Activated PKC␣ Associates with nELAV Proteins and Increases Their
Threonine Phosphorylation. We next sought to determine whether the biological effects on nELAV proteins induced by PKC stimulation could be due to a direct action of specific members of this serine͞threonine protein kinase family on the nELAV targets. Of the PKC isozymes regulated by diacylglycerol and its mimicking compounds (for a review, see ref. 38) , we focused our attention on PKC␣, because down-regulation of this isozyme has been shown to be incompatible with neuronal differentiation of SH-SY5Y cells (39), a process that is known to depend on the nELAV proteins in other neuronal differentiation models (29, 33) . Immunocytochemical analysis ( Fig. 2A) shows a clear PMA-induced colocalization of the PKC␣ and nELAV signals. This result is confirmed by the experiments reported in Fig. 2B , where the cytoskeletal fraction of SH-SY5Y cells is immunoprecipitated with the anti-ELAV 16A11 mAb, and PKC␣ is then detected in the pellet in the presence and absence of PKC stimulation by PMA. The association with PKC␣ was dramatically increased when PKC was activated (ϩ222%, P Ͻ 0.05 in the cytoskeleton), as also confirmed by the reverse experiment (not shown). Taken together, these results and the previous ones suggest that treatment of neuroblastoma cells with diacylglycerol-mimicking compounds promotes an increase and a cytoplasmic recruitment of nELAV proteins specifically at the level of the cytoskeletal network, where they associate with the translocated PKC␣ isoform.
To explore the functional consequence of the formation of this complex, we looked at the nELAV levels in the cytoskeletal fraction of cell lysates that were immunoprecipitated with anti-phosphoserine and phosphothreonine antibodies or reversely pulled down with the 16A11 mAb and analyzed with phosphoserine and phosphothreonine antibodies. Only the threonine phosphorylation of ELAV proteins increased after PMA treatment (ϩ106%, P Ͻ 0.01; Fig. 2C ). Therefore, PKC activation by PMA enhances threonine phosphorylation of nELAV proteins in SH-SY5Y neuroblastoma cells.
Recruitment of nELAV Proteins Requires PKC␣ Activation. To substantiate the correlative evidence of PKC␣ involvement in nELAV protein activation, we wanted to establish the requirement of this specific isozyme for the effects of PMA treatment on nELAV proteins. We adopted two models of PKC␣ knock-down, a genetic model represented by a clone of the same SH-SY5Y cells obtained by stable antisense expression of the PKC␣ ORF (34) and a pharmacological model of inhibition by the selective PKC␣ inhibitor Gö6976 (40) . In the untreated, knocked-down SH-SY5Y neuroblasts (PKC␣ KD), as expected, PKC␣ protein levels measured by Western blotting were reduced in all cell fractions, being almost undetectable in the cytoskeleton (Ϫ53%, P Ͻ 0.0001 in the cytosol; Ϫ42%, P Ͻ 0.0001 in the membrane; and Ϫ65%, P Ͻ 0.005 in the cytoskeleton; Fig. 3A) , whereas the level of nELAV proteins was unchanged. In the PKC␣ KD SH-SY5Y cells and in the WT SH-SY5Y cells preincubated for 30 min with 2 M Gö6976, PMA treatment was ineffective in inducing an increase of nELAV protein levels in all of the cellular fractions examined (Fig. 3 B and C) , producing no detectable change in the knocked-down model and a statistically insignificant change with the PKC␣ inhibitor. From these experiments, we conclude that the enhancing effect of PMA on nELAV protein levels is mediated by PKC␣.
Stabilization of the GAP-43 mRNA and Increased Translation of the
GAP-43
Protein at the Cytoskeleton by PKC␣ Activation. Among the neuronal genes whose mRNA is a target of the nELAV proteins, GAP-43 is by far the most well characterized. From in vitro and in vivo experiments, we know that the binding of nELAV proteins to GAP-43 mRNA induces its stabilization and an increase in the whole-cell GAP-43 protein levels, with profound biological effects. Therefore, we measured kinetically the GAP-43 mRNA decay rate in our cell model after the addition of DRB, a molecule able to specifically block transcription (41) . The 15-min PMA treatment induced a marked, persistent stabilization of the GAP-43 transcript, raising the remaining intact mRNA from 30% to 50% of the initial levels after 8 h (Fig. 4A) . Again, the dependence of this effect on PKC␣ was clearly shown with the demonstration of its absence in the PKC␣-deficient KD SH-SY5Y cells, which bear a basically more unstable GAP-43 mRNA whose decay rate remains unchanged after PMA treatment (dotted lines in Fig. 4A ). We then examined GAP-43 protein levels by Western blotting after 15 min of PMAmediated PKC activation. We found that there was an increase in GAP-43 protein content, which, unexpectedly, was limited to the cytoskeletal fraction (ϩ38%, P Ͻ 0.005; Fig. 4 B and C) . This increase was prevented by Gö6976 pretreatment (Fig. 4D) and did not occur in the KD SH-SY5Y cells (not shown), again demonstrating the need of expressed and enzymatically active PKC␣ for its occurrence.
Pharmacological Modulation of the PKC␣-Dependent nELAV Recruitment Pathway in the Mammalian Brain. Unlike phorbol esters, which are tumor promoters and therefore do not represent viable options for drug development, PKC activators belonging to the class of diacylglycerol-mimicking compounds have been proposed as potential drugs for applications in oncology (42) and neurodegeneration (43, 44) . Bryostatin-1 is one of these compounds and has already been shown to be devoid of important side effects and actively studied in phase I and II clinical trials as an anticancer agent (45) . Given the ability of bryostatin-1 to recruit nELAV proteins in our neuroblastoma cell model (Fig. 1) , we checked whether this agonist would be effective in doing the same when administered in vivo into the mammalian brain. Fig. 5 shows that after 24 h of intraventricular injection of bryostatin-1 in rats, nELAV proteins undergo a sustained up-regulation in all of the hippocampal subregions, in a way reminiscent of their activation after spatial learning (46) .
Discussion
The dramatic biological activity of nELAV proteins has been clear since the first description of these genes, the report on the Drosophila elav locus (47) whose mutants dye as embryos for the absence of a fully developed nervous system. Subsequently, studies of ectopic expression in vertebrates (48) and experiments of gene overexpression͞knock-down in ''neural'' model cell cultures (33, 49, 50) have revealed a key role for nELAV proteins in the differentiation of the neuronal lineage. In parallel with investigations about their biological activity, biochemical studies have established the molecular function of ELAV proteins as stabilizers of the target mRNAs, an activity demonstrated both for the neuronal and the ubiquitous (HuR) members of the family (for reviews, see refs. 23 and 24). Nevertheless, neither the mechanism(s) by which ELAV proteins counteract decay of bound mRNAs nor the cellular pathways by which this activity is triggered are known. The present work sheds light on the second problem, demonstrating the existence of a pathway involving PKC␣ for nELAV protein recruitment and activity. The evidence comes from the demonstration that in cultured neuroblastoma cells, PKC activators induce nELAV proteins to be exported from the nucleus and to increase their total cell content at the level of the cytoskeleton, up-regulating at the same time and in the same cell compartment the GAP-43 protein, a nELAV target. Both of these increases can be prevented by the specific inactivation of the PKC␣ isozyme, suggesting that this isozyme, among the others of the family, plays the major role in the process. PKC␣ colocalization with nELAV proteins after stimulation and the increase in their threonine phosphorylation are also in agreement with a direct kinase activity of PKC␣ on HuB, HuC, and HuD proteins, which could take place at the five conserved putative threonine PKC phosphorylation sites that they share in the primary amino acid sequence. Given the very short time frame of nELAV and GAP-43 protein up-regulation induced by PKC stimulation (15 min), it is tempting to speculate that this PKC-induced control of gene expression is exerted at the translational level, which would be in agreement with the polysomal localization of nELAV proteins in the neuronal cytoplasm (30, 31, 49, 51) and with their proposed activity of translational enhancement (49, 52, 53) . The up-regulation of the nELAV proteins themselves could be an autoregulation mechanism: We already know that the Drosophila ELAV protein is autoregulated at the mRNA level (54) and that murine HuB mRNA is bound by the HuB protein itself (55) . An autologous binding activity is described for other RBPs acting at the translational level, such as fragile X mental retardation protein (56) , poly(A)-binding protein (57) , and ribosomal protein S15 (58) . The action of PKC on nELAV protein targets at the translational level is also suggested by experiments of disruption of this activity by translational inhibitors (unpublished data).
But what are the possible biological outcomes of PKC-induced activation of nELAV proteins? First of all, nELAV activation by PKC agonists could be a key event in the program of neuronal differentiation during development. Expression of nELAV proteins during the shaping of the mammalian nervous system is a tightly regulated process (59, 60) , and PKC-dependent signal transduction events, fundamental for specific aspects of nervous system development (61, 62) , can provide, in view of our findings, an additional level of modulation of nELAV activity. In vitro models recapitulating neuronal differentiation provide correlative evidence of this interaction. In PC12 pheochromocytoma cells exposed to nerve growth factor, neurite outgrowth appears to be both PKC- (63, 64) and HuD-dependent (33), whereas neural-like differentiation of teratocarcinoma NT2 cells involves PKC function (65, 66) and is promoted by HuB overexpression (49) .
Moreover, the functional link between PKC and ELAV proteins could be involved in another important cell program of nondevelopmental neural plasticity, nerve regeneration. All diacylglyceroldependent PKC isoforms are intensely up-regulated in the growth cone of regenerating axons in the rat peripheral nervous system, an increase that takes place within hours of nerve injuries and costimulates axonal regeneration (67, 68) , whereas PKC inhibition has been found to decrease the in vitro regenerative nerve growth potential (69, 70) . The nELAV HuD protein was shown to be overexpressed in rat dorsal root ganglia neurons during peripheral nerve regeneration (71) .
Finally, a substantial body of evidence supports a functional role for PKC activation and redistribution in invertebrate (72, 73) , avian (74) , and mammalian (75-81) models of memory. We previously proposed a physiological role for nELAV proteins in controlling gene expression in memory formation (37, 46) . The evidence came from region-specific up-regulation of the nELAV proteins in hippocampal neurons of rodents trained in spatial discrimination tasks, which was associated with increased binding and increased steady-state levels of the GAP-43 mRNA. In vivo knock-down of HuC impaired learning performance and specifically prevented GAP-43 mRNA up-regulation, demonstrating the need of these biochemical events for memory formation (37) . Interestingly, these effects were particularly evident in the cytoskeletal compartment of hippocampal lysates and were characterized by increased colocalization of the HuD protein and GAP-43 mRNA (46) . A report extended hippocampal HuD up-regulation to another nonspatial learning paradigm, fear conditioning, demonstrating the generality of nELAV involvement in memory formation (82) .
Therefore, the PKC␣-dependent nELAV protein recruitment and activation described here could sustain nELAV protein function in the differentiation, regeneration, and learning nervous system programs. Our in vivo demonstration of hippocampal nELAV protein up-regulation by bryostatin-1 represents experimental evidence that the role of nELAV proteins in these programs could be pharmacologically modulated by acting on PKC by compounds already shown to be effective in models of neurodegeneration (43) .
Further experiments are needed to address the relevance of this pathway for each of the mentioned major neural programs involving nELAV proteins and also for its role in nonneural systems involving the HuR protein and characterized by ARE-dependent modulation of gene expression. Moreover, the generality of the PKC signaling on ELAV protein recruitment and activation could allow the proposal of pharmacological approaches aimed both at the enhancement of this function in conditions of decreased neuronal plasticity and at its inhibition in conditions such as paraneoplastic syndromes (83) and colorectal cancer (84, 85) that are already associated with improper expression, respectively, of the neuronal and ubiquitous ELAV proteins.
